BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 28478688)

  • 21. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
    Sarkar R; Xiao W; Kazazian HH
    J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B.
    Sarangi P; Kumar N; Sambasivan R; Ramalingam S; Amit S; Chandra D; Jayandharan GR
    Thromb Res; 2024 Jun; 238():151-160. PubMed ID: 38718473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
    Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
    Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene-based continuous expression of FVIIa for the treatment of hemophilia.
    Margaritis P
    Front Biosci (Schol Ed); 2012 Jan; 4(1):287-99. PubMed ID: 22202061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
    Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
    Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
    Patel SR; Lundgren TS; Spencer HT; Doering CB
    Front Immunol; 2020; 11():494. PubMed ID: 32351497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy for the hemophilias.
    VandenDriessche T; Collen D; Chuah MK
    J Thromb Haemost; 2003 Jul; 1(7):1550-8. PubMed ID: 12871290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.
    Samelson-Jones BJ; Arruda VR
    Front Immunol; 2020; 11():618. PubMed ID: 32425925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.
    Monahan PE; Lothrop CD; Sun J; Hirsch ML; Kafri T; Kantor B; Sarkar R; Tillson DM; Elia JR; Samulski RJ
    Mol Ther; 2010 Nov; 18(11):1907-16. PubMed ID: 20700109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.